Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019
May 13 2019 - 1:30PM
Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the
Company”) today announces that it will report First Quarter 2019
financial results for the period ended March 31, 2019, after the
market close on Wednesday, May 15, 2019.
Management will host a conference call that same day at 4:30
p.m. Eastern Time to review financial results, corporate
highlights, and to provide an update on developments. Following
management’s formal remarks, there will be a question and answer
session with equity analysts.
Participants are asked to preregister for the call through the
following link http://dpregister.com/10131658. Please note
that registered participants will receive their dial in number upon
registration and will dial directly into the call without delay.
Those without internet access or who are unable to pre-register may
dial in by calling: 1-866-777-2509 (domestic), 1-412-317-5413
(international). All callers should dial in approximately 10
minutes prior to the scheduled start time and ask to be joined into
the Precision Therapeutics Inc., call.
The conference call will also be available through a live
webcast, which can be accessed via the following link:
https://services.choruscall.com/links/aipt190515.html, which will
also be available through the company’s website at:
http://investors.skylinemedical.com/events-and-presentations.
A replay of the call will be available approximately one hour
after the end of the call through June 15, 2019. The replay can be
accessed via Precision’s website or by dialing 1-877-344-7529
(U.S.) or +1-412-317-0088 (international). The replay conference
playback code is 10131658.
A webcast replay of the call will also be available
approximately one hour after the end of the call through August 15,
2019. The replay can be accessed through the above links.
About Precision Therapeutics Inc.
Precision Therapeutics (NASDAQ: AIPT) operates through its three
wholly owned subsidiaries, Helomics, TumorGenesis and Skyline
Medical. Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by
providing an evidence-based roadmap for therapy. In addition to its
proprietary precision oncology platform, Helomics offers boutique
CRO services that leverage its TruTumor™, patient-derived tumor
models coupled to a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform (D-CHIP) to provide a tailored solution to
its clients’ specific needs. Precision’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the
laboratory, which essentially “fools” cancer cells into thinking
they are still growing inside a patient. Its proprietary Oncology
Discovery Technology Platform kits will assist researchers and
clinicians to identify which cancer cells bind to specific
biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate
and help categorize an individual patient’s heterogeneous tumor
samples to enable the development of patient specific treatment
options. Helomics and TumorGenesis are focused on ovarian cancer.
Precision’s Skyline Medical subsidiary markets its patented and FDA
cleared STREAMWAY System which automates the collection,
measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through
both domestic and international divisions. The company has achieved
sales in five of the seven continents through both direct sales and
distributor partners. For more information, please visit
www.precisiontherapeutics.com.
Forward-looking StatementsCertain of the
matters discussed in the press release contain forward-looking
statements that involve material risks to and uncertainties in the
Company’s business that may cause actual results to differ
materially from those anticipated by the statements made herein.
Such risks and uncertainties include (i) risks related to our
partnerships with other companies, including the need to negotiate
the definitive agreements; possible failure to realize anticipated
benefits of these partnerships; and costs of providing funding to
our partner companies, which may never be repaid or provide
anticipated returns; and (ii) other risks and uncertainties
relating to the Company that include, among other things, current
negative operating cash flows and a need for additional funding to
finance our operating plan; the terms of any further financing,
which may be highly dilutive and may include onerous terms;
unexpected costs and operating deficits, and lower than expected
sales and revenues; sales cycles that can be longer than expected,
resulting in delays in projected sales or failure to make such
sales; uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance, if our product is not accepted by our potential
customers, it is unlikely that we will ever become profitable;
adverse economic conditions; adverse results of any legal
proceedings; the volatility of our operating results and financial
condition; inability to attract or retain qualified senior
management personnel, including sales and marketing personnel; our
ability to establish and maintain the proprietary nature of our
technology through the patent process, as well as our ability to
possibly license from others patents and patent applications
necessary to develop products; Precision’s ability to implement its
long range business plan for various applications of its
technology; Precision’s ability to enter into agreements with any
necessary marketing and/or distribution partners and with any
strategic or joint venture partners; the impact of competition, the
obtaining and maintenance of any necessary regulatory clearances
applicable to applications of Precision’s technology; and
management of growth and other risks and uncertainties that may be
detailed from time to time in the Company’s reports filed with the
SEC, which are available for review at www.sec.gov. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of Precision’s financial position. See
Precision’s most recent Annual Report on Form 10-K, and subsequent
reports and other filings at www.sec.gov.
Contacts:Investor RelationsBret Shapiro, Managing PartnerCORE
IR(516) 222-2560 brets@coreir.com
Media Jules Abraham CORE IR917-885-7378julesa@coreir.com
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Sep 2023 to Sep 2024